1.Dyerberg J & Bang HO (1979) Lipid metabolism, atherogenesis, and haemostasis in Eskimos: The role of the prostaglandin-3 family. Haemostasis 8, 227–233.
2.Serhan CN & Chiang N (2008) Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus. Br J Pharmacol 153, S200–S215.
3.von Schacky C & Harris WS (2007) Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 73, 310–315.
4.Hu FB & Willett WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288, 2569–2578.
5.He K, Song Y, Daviglus ML et al. (2004) Fish consumption and incidence of stroke: A meta-analysis of cohort studies. Stroke 35, 1538–1542.
6.Keli SO, Feskens EJ & Kromhout D (1994) Fish consumption and risk of stroke. The Zutphen Study. Stroke 25, 328–332.
7.Lichtenstein AH, Appel LJ, Brands M et al. (2006) Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 114, 82–96.
8.SACN. (2004) Scientiﬁc Advisory Committee on Nutrition – Advice on Fish Consumption: Beneﬁts and Risks. London: FSA.
9.Hooper L, Thompson RL, Harrison RA et al. (2006) Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ 332, 752–760.
10.Kromhout D, Giltay EJ & Geleijnse JM (2010) n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 2015–2026.
11.Filion K, El Khoury F, Bielinski M et al. . (2010) Omega-3 fatty acids in high-risk cardiovascular patients: A meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 10, 24.
12.Wendland E, Farmer A, Glasziou P et al. (2006) Effect of alpha linolenic acid on cardiovascular risk markers: A systematic review. Heart 92, 166–169.
13.Burdge GC & Calder PC (2005) Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 45, 581–597.
14.Gerster H (1998) Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res 68, 159–173.
15.Konkel A & Schunck W-H (2011) Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 1814, 210–222.
16.Hashimoto M, Hossain S, Yamasaki H et al. (1999) Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 34, 1297–1304.
17.Krey G, Braissant O, L'Horset F et al. (1997) Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11, 779–791.
18.Weldon SM, Mullen AC, Loscher CE et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250–258.
19.Caputo M, Zirpoli H, Torino G et al. . (2011) Selective regulation of UGT1A1 and SREBP-1c mRNA expression by docosahexaenoic, eicosapentaenoic and arachidonic acids. J Cell Physiol 226, 187–193.
20.Cullen P (2000) Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86, 943–949.
21.Stalenhoef AF & de Graaf J (2008) Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 19, 355–361.
22.Eslick GD, Howe PR, Smith C et al. (2009) Benefits of fish oil supplementation in hyperlipidemia: A systematic review and meta-analysis. Int J Cardiol 136, 4–16.
23.Mattar M & Obeid O (2009) Fish oil and the management of hypertriglyceridemia. Nutr Health 20, 41–49.
24.Grimsgaard S, Bonaa KH, Hansen JB et al. (1997) Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 66, 649–659.
25.Egert S, Kannenberg F, Somoza V et al. (2009) Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr 139, 861–868.
26.Mori TA, Burke V, Puddey IB et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 1085–1094.
27.Rambjor GS, Walen AI, Windsor SL et al. . (1996) Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids 31, Suppl, S45–S49.
28.Buckley R, Shewring B, Turner R et al. (2004) Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 92, 477–483.
29.Park Y & Harris WS (2003) Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 44, 455–463.
30.Olano-Martin E, Anil E, Caslake MJ et al. (2010) Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 209, 104–110.
31.Woodman RJ, Mori TA, Burke V et al. (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76, 1007–1015.
32.Nestel P, Shige H, Pomeroy S et al. (2002) The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 76, 326–330.
33.Holub BJ (2009) Docosahexaenoic acid (DHA) and cardiovascular disease risk factors. Prostaglandins Leukot Essent Fatty Acids 81, 199–204.
34.Theobald HE, Chowienczyk PJ, Whittall R et al. (2004) LDL cholesterol–raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 79, 558–563.
35.Kelley DS, Siegel D, Vemuri M et al. (2007) Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 86, 324–333.
36.Geppert J, Kraft V, Demmelmair H et al. (2006) Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: A randomised trial. Br J Nutr 95, 779–786.
37.Nelson G, Schmidt P, Bartolini G et al. (1997) The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans. Lipids 32, 1137–1146.
38.Kondo A, Muranaka Y, Ohta I et al. (2001) Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 47, 893–900.
39.Morgan J, Carey C, Lincoff A et al. (2004) High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep 6, 359–365.
40.Chan DC, Watts GF, Nguyen MN et al. (2006) Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 84, 37–43.
41.Wilkinson P, Leach C, Ah-Sing EE et al. (2005) Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 181, 115–124.
42.Agren JJ, Hanninen O, Julkunen A et al. (1996) Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr 50, 765–771.
43.Griffin MD, Sanders TA, Davies IG et al. (2006) Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: The OPTILIP Study. Am J Clin Nutr 84, 1290–1298.
44.Nozaki S, Matsuzawa Y, Hirano K et al. (1992) Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res 62, 256–260.
45.Liao FH, Liou TH, Shieh MJ et al. (2010) Effects of different ratios of monounsaturated and polyunsaturated fatty acids to saturated fatty acids on regulating body fat deposition in hamsters. Nutrition 26, 811–817.
46.Harris WS, Miller M, Tighe AP et al. (2008) Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 197, 12–24.
47.Burdge GC, Powell J, Dadd T et al. (2009) Acute consumption of fish oil improves postprandial VLDL profiles in healthy men aged 50–65 years. Br J Nutr 102, 160–165.
48.Howell Iii G, Deng X, Yellaturu C et al. (2009) N-3 polyunsaturated fatty acids suppress insulin-induced SREBP-1c transcription via reduced trans-activating capacity of LXR[alpha]. Biochim Biophys Acta 1791, 1190–1196.
49.Kajikawa S, Harada T, Kawashima A et al. (2009) Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice. Prostaglandins Leukot Essent Fatty Acids 80, 229–238.
50.Harris WS & Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17, 387–393.
51.Chambrier C, Bastard JP, Rieusset J et al. (2002) Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res 10, 518–525.
52.Arai T, Kim HJ, Chiba H et al. (2009) Interaction of fenofibrate and fish oil in relation to lipid metabolism in mice. J Atheroscler Thromb 16, 283–291.
53.Le Jossic-Corcos C, Gonthier C, Zaghini I et al. (2005) Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. Biochem J 385, 787–794.
54.Sone H, Takahashi A, Shimano H et al. (2002) HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 71, 2403–2412.
55.Pontrelli L, Parris W, Adeli K et al. (2002) Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 51, 334–342.
56.Ikewaki K, Terao Y, Ozasa H et al. (2009) Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia. J Atheroscler Thromb 16, 51–56.
57.Nordoy A (2002) Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease. Minerva Med 93, 357–363.
58.Das UN (2008) Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 7, 37.
59.Turnbull F, Neal B, Ninomiya T et al. (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ 336, 1121–1123.
60.Law MR, Morris JK & Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665.
61.Mori TA (2006) Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 33, 842–846.
62.Morris MC, Sacks F & Rosner B (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88, 523–533.
63.Geleijnse JM, Giltay EJ, Grobbee DE et al. (2002) Blood pressure response to fish oil supplementation: Metaregression analysis of randomized trials. J Hypertens 20, 1493–1499.
64.Grimsgaard S, Bonaa K, Hansen J et al. (1998) Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 68, 52–59.
65.Theobald HE, Goodall AH, Sattar N et al. (2007) Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 137, 973–978.
66.Pickering TG, Shimbo D & Haas D (2006) Ambulatory blood-pressure monitoring. N Engl J Med 354, 2368–2374.
67.Ohkubo T, Imai Y, Tsuji I et al. (1997) Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: A pilot study in Ohasama. J Hypertens 15, 357–364.
68.Staessen JA, Thijs L, Fagard R et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial investigators. JAMA 282, 539–546.
69.Mori TA, Bao DQ, Burke V et al. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253–260.
70.Perret-Guillaume C, Joly L & Benetos A (2009) Heart rate as a risk factor for cardiovascular disease. Prog Cardiovasc Dis 52, 6–10.
71.Mozaffarian D, Geelen A, Brouwer et al. (2005) Effect of fish oil on heart rate in humans: A meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.
72.Stark KD & Holub BJ (2004) Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 79, 765–773.
73.McLennan PL (2001) Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 36, Suppl, S111–S114.
74.Christensen JH, Skou HA, Fog L et al. (2001) Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation 103, 651–657.
75.Holguin F, Tellez-Rojo MM, Lazo M et al. (2005) Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly. Chest 127, 1102–1107.
76.Christensen JH, Christensen MS, Dyerberg J et al. (1999) Heart rate variability and fatty acid content of blood cell membranes: A dose-response study with n-3 fatty acids. Am J Clin Nutr 70, 331–337.
77.Svensson M, Schmidt EB, Jorgensen KA et al. (2007) The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis. J Ren Nutr 17, 243–249.
78.Geelen A, Zock PL, Swenne CA et al. . (2003) Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. Am Heart J 146, E4.
79.Dyerberg J, Eskesen DC, Andersen PW et al. (2004) Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 58, 1062–1070.
80.Mozaffarian D, Stein PK, Prineas RJ et al. (2008) Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation 117, 1130–1137.
81.Xiao YF, Gomez AM, Morgan JP et al. (1997) Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 94, 4182–4187.
82.Li GR, Sun HY, Zhang XH et al. (2009) Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes. Cardiovasc Res 81, 286–293.
83.Xiao YF, Sigg DC & Leaf A (2005) The antiarrhythmic effect of n-3 polyunsaturated fatty acids: Modulation of cardiac ion channels as a potential mechanism. J Membr Biol 206, 141–154.
84.Kang JX & Leaf A (1996) Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci USA 93, 3542–3546.
85.Grynberg A, Fournier A, Sergiel JP et al. (1995) Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. J Mol Cell Cardiol 27, 2507–2520.
86.Hashimoto M, Shinozuka K, Gamoh S et al. (1999) The hypotensive effect of docosahexaenoic acid is associated with the enhanced release of ATP from the caudal artery of aged rats. J Nutr 129, 70–76.
87.Nelson MR, Stepanek J, Cevette M et al. . (2010) Noninvasive measurement of central vascular pressures with arterial tonometry: Clinical revival of the pulse pressure waveform? Mayo Clin Proc 85, 460–472.
88.Millasseau SC, Ritter JM, Takazawa K et al. (2006) Contour analysis of the photoplethysmographic pulse measured at the finger. J Hypertens 24, 1449–1456.
89.Mark G & Sanders TA (1994) The influence of different amounts of n-3 polyunsaturated fatty acids on bleeding time and in vivo vascular reactivity. Br J Nutr 71, 43–52.
90.Shimokawa H, Aarhus LL & Vanhoutte PM (1988) Dietary omega 3 polyunsaturated fatty acids augment endothelium-dependent relaxation to bradykinin in coronary microvessels of the pig. Br J Pharmacol 95, 1191–1196.
91.Shimokawa H & Vanhoutte PM (1988) Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 78, 1421–1430.
92.Leeson CPM, Mann A, Kattenhorn M et al. (2002) Relationship between circulating n-3 fatty acid concentrations and endothelial function in early adulthood. Eur Heart J 23, 216–222.
93.Chin JP, Gust AP, Nestel PJ et al. (1993) Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 21, 22–28.
94.Goodfellow J, Bellamy MF, Ramsey MW et al. (2000) Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 35, 265–270.
95.Khan F, Elherik K, Bolton-Smith C et al. (2003) The effects of dietary fatty acid supplementation on endothelial function and vascular tone in healthy subjects. Cardiovasc Res 59, 955–962.
96.McVeigh GE, Brennan GM, Johnston GD et al. (1993) Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36, 33–38.
97.Mori TA, Watts GF, Burke V et al. (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102, 1264–1269.
98.Shah AP, Ichiuji AM, Han JK et al. (2007) Cardiovascular and endothelial effects of fish oil supplementation in healthy volunteers. J Cardiovasc Pharmacol Ther 12, 213–219.
99.Tagawa H, Shimokawa H, Tagawa T et al. (1999) Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 33, 633–640.
100.Tagawa T, Hirooka Y, Shimokawa H et al. (2002) Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 25, 823–829.
101.Walser B, Giordano RM & Stebbins CL (2006) Supplementation with omega-3 polyunsaturated fatty acids augments brachial artery dilation and blood flow during forearm contraction. Eur J Appl Physiol 97, 347–354.
102.Rizza S, Tesauro M, Cardillo C et al. (2009) Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis 206, 569–574.
103.Schiano V, Laurenzano E, Brevetti G et al. (2008) Omega-3 polyunsaturated fatty acid in peripheral arterial disease: Effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr 27, 241–247.
104.De Berrazueta JR, Gómez de Berrazueta JM, Amado Señarís JA et al. (2009) A diet enriched with mackerel (Scomber scombrus)–derived products improves the endothelial function in a senior population (Prevención de las Enfermedades Cardiovasculares: Estudio Santoña – PECES project). Eur J Clin Invest 39, 165–173.
105.Morgan DR, Dixon LJ, Hanratty CG et al. (2006) Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol 97, 547–551.
106.Stirban A, Nandrean S, Gotting C et al. (2010) Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91, 808–813.
107.Wright SA, O'Prey FM, McHenry MT et al. (2008) A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 67, 841–848.
108.Okumura T, Fujioka Y, Morimoto S et al. (2002) Eicosapentaenoic acid improves endothelial function in hypertriglyceridemic subjects despite increased lipid oxidizability. Am J Med Sci 324, 247–253.
109.Engler MM, Engler MB, Malloy M et al. (2004) Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study. Int J Clin Pharmacol Ther 42, 672–679.
110.Harris WS, Rambjor GS, Windsor SL et al. (1997) n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr 65, 459–464.
111.Hamazaki T, Urakaze M, Sawazaki S et al. (1988) Comparison of pulse wave velocity of the aorta between inhabitants of fishing and farming villages in Japan. Atherosclerosis 73, 157–160.
112.McVeigh GE, Brennan GM, Cohn JN et al. (1994) Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 14, 1425–1429.
113.Wang S, Ma AQ, Song SW et al. (2008) Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. Eur J Clin Nutr 62, 1426–1431.
114.Satoh N, Shimatsu A, Kotani K et al. (2009) Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 32, 1004–1008.
115.Tomiyama H, Takazawa K, Osa S et al. (2005) Do eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia? A preliminary study. Hypertens Res 28, 651–655.
116.Jonk AM, Houben AJHM, de Jongh RT et al. (2007) Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 22, 252–260.
117.Antonios TF, Singer DR, Markandu ND et al. (1999) Structural skin capillary rarefaction in essential hypertension. Hypertension 33, 998–1001.
118.Mitasikova M, Smidova S, Macsaliova A et al. (2008) Aged male and female spontaneously hypertensive rats benefit from n-3 polyunsaturated fatty acids supplementation. Physiol Res 57, Suppl 2, S39–S48.
119.Conde CMS, Cyrino FZGA, Bottino DA et al. (2007) Longchain n-3 polyunsaturated fatty acids and microvascular reactivity: Observation in the hamster cheek pouch. Microvasc Res 73, 237–247.
120.Awan ZA, Wester T & Kvernebo K (2010) Human microvascular imaging: A review of skin and tongue videomicroscopy techniques and analysing variables. Clin Physiol Funct Imaging 30, 79–88.
121.Yaqoob P (2009) The nutritional significance of lipid rafts. Annu Rev Nutr 29, 257–282.
122.Li Q, Zhang Q, Wang M et al. (2007) Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 466, 250–259.
123.Li Q, Zhang Q, Wang M et al. (2007) Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase. Biochimie 89, 169–177.
124.Hishinuma T, Yamazaki T & Mizugaki M (1999) Effects of long-term supplementation of eicosapentanoic and docosahexanoic acid on the 2-, 3-series prostacyclin production by endothelial cells. Prostaglandins Other Lipid Mediat 57, 333–340.
125.Matsumoto T, Nakayama N, Ishida K et al. (2009) Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J Pharmacol Exp Ther 329, 324–334.
126.Engler MB & Engler MM (2000) Docosahexaenoic acid-induced vasorelaxation in hypertensive rats: Mechanisms of action. Biol Res Nurs 2, 85–95.
127.Singh TU, Kathirvel K, Choudhury S et al. (2010) Eicosapentaenoic acid-induced endothelium-dependent and -independent relaxation of sheep pulmonary artery. Eur J Pharmacol 636, 108–113.
128.Engler MM, Engler MB, Pierson DM et al. (2003) Effects of docosahexaenoic acid on vascular pathology and reactivity in hypertension. Exp Biol Med (Maywood) 228, 299–307.
129.Engler MB, Ma YH & Engler MM (1999) Calcium-mediated mechanisms of eicosapentaenoic acid-induced relaxation in hypertensive rat aorta. Am J Hypertens 12, 1225–1235.
130.Conquer JA & Holub BJ (1996) Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 126, 3032–3039.
131.Ross R (1993) The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362, 801–809.
132.Shaw DI, Hall WL, Jeffs NR et al. (2007) Comparative effects of fatty acids on endothelial inflammatory gene expression. Eur J Nutr 46, 321–328.
133.De Caterina R & Massaro M (2005) Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. J Membr Biol 206, 103–116.
134.De Caterina R, Cybulsky MI, Clinton SK et al. (1994) The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 14, 1829–1836.
135.De Caterina R, Cybulsky MA, Clinton SK et al. (1995) Omega-3 fatty acids and endothelial leukocyte adhesion molecules. Prostaglandins Leukot Essent Fatty Acids 52, 191–195.
136.Weber C, Erl W, Pietsch A et al. (1995) Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 15, 622–628.
137.Goua M, Mulgrew S, Frank J et al. . (2008) Regulation of adhesion molecule expression in human endothelial and smooth muscle cells by omega-3 fatty acids and conjugated linoleic acids: Involvement of the transcription factor NF-kappaB? Prostaglandins Leukot Essent Fatty Acids 78, 33–43.
138.Farzaneh-Far R, Harris WS, Garg S et al. (2009) Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 205, 538–543.
139.Ferrucci L, Cherubini A, Bandinelli S et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439–446.
140.Perunicic-Pekovic GB, Rasic ZR, Pljesa SI et al. (2007) Effect of n-3 fatty acids on nutritional status and inflammatory markers in haemodialysis patients. Nephrology (Carlton) 12, 331–336.
141.Rasic-Milutinovic Z, Perunicic G, Pljesa S et al. (2007) Effects of n-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 29, 321–329.
142.Damsgaard CT, Lauritzen L, Calder PC et al. (2009) Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men. J Nutr 139, 1410–1414.
143.Trebble T, Arden NK, Stroud MA et al. (2003) Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr 90, 405–412.
144.Caughey G, Mantzioris E, Gibson R et al. (1996) The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63, 116–122.
145.Bowden RG, Wilson RL, Deike E et al. (2009) Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract 24, 508–512.
146.Bloomer RJ, Larson DE, Fisher-Wellman KH et al. . (2009) Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study. Lipids Health Dis 8, 36.
147.Yusof HM, Miles EA & Calder P (2008) Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins Leukot Essent Fatty Acids 78, 219–228.
148.Fujioka S, Hamazaki K, Itomura M et al. (2006) The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects – a randomized, placebo-controlled, double-blind study. J Nutr Sci Vitaminol (Tokyo) 52, 261–265.
149.Burns T, Maciejewski SR, Hamilton WR et al. (2007) Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio. Pharmacotherapy 27, 633–638.
150.Blok WL, Deslypere JP, Demacker PN et al. (1997) Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. Eur J Clin Invest 27, 1003–1008.
151.Balk EM, Lichtenstein AH, Chung M et al. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review. Atherosclerosis 189, 19–30.
152.Mori TA, Woodman RJ, Burke V et al. (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772–781.
153.Kelley DS, Siegel D, Fedor DM et al. (2009) DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr 139, 495–501.
154.Calder PC (2008) Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 52, 885–897.
155.Mickleborough TD, Tecklenburg SL, Montgomery GS et al. (2009) Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells. Clin Nutr 28, 71–77.
156.Gronn M, Christensen E, Hagve TA et al. (1991) Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. Biochim Biophys Acta 1081, 85–91.
157.Tian H, Lu Y, Sherwood AM et al. (2009) Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Visual Sci 50, 3613–3620.
158.Saynor R, Verel D & Gillott T (1984) The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 50, 3–10.
159.Lorenz R, Spengler U, Fischer S et al. (1983) Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 67, 504–511.
160.Saynor R & Verel D (1982) Eicosapentaenoic acid, bleeding time, and serum lipids. Lancet 320, 272–272.
161.Green D, Barreres L, Borensztajn J et al. (1985) A double-blind, placebo-controlled trial of fish oil concentrate (MaxEpa) in stroke patients. Stroke 16, 706–709.
162.Hartweg J, Farmer AJ, Holman RR et al. (2009) Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol 20, 30–38.
163.Siess W, Roth P, Scherer B et al. (1980) Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet 1, 441–444.
164.Mann N, Sinclair A, Pille M et al. (1997) The effect of short-term diets rich in fish, red meat, or white meat on thromboxane and prostacyclin synthesis in humans. Lipids 32, 635–644.
165.Mori TA, Beilin LJ, Burke V et al. (1997) Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17, 279–286.
166.Din JN, Harding SA, Valerio CJ et al. (2008) Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 197, 290–296.
167.Nomura S, Kanazawa S & Fukuhara S (2003) Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus. J Diabetes Complications 17, 153–159.
168.Park Y & Harris W (2002) EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids 37, 941–946.
169.Wojenski CM, Silver MJ & Walker J (1991) Eicosapentaenoic acid ethyl ester as an antithrombotic agent: Comparison to an extract of fish oil. Biochim Biophys Acta 1081, 33–38.
170.Hashimoto M, Hossain S & Shido O (2006) Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity. Mol Cell Biochem. 293, 1–8.
171.Adan Y, Shibata K, Sato M et al. (1999) Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis in hypercholesterolemic rats. Biosci Biotechnol Biochem 63, 111–119.
172.Yamada N, Shimizu J, Wada M et al. (1998) Changes in platelet aggregation and lipid metabolism in rats given dietary lipids containing different n-3 polyunsaturated fatty acids. J Nutr Sci Vitaminol (Tokyo) 44, 279–289.
173.von Schacky C & Weber PC (1985) Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76, 2446–2450.
174.Woodman RJ, Mori TA, Burke V et al. (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166, 85–93.
175.Guillot N, Caillet E, Laville M et al. (2009) Increasing intakes of the long-chain omega-3 docosahexaenoic acid: Effects on platelet functions and redox status in healthy men. FASEB J. 23, 2909–2916.
176.Robinson JG & Stone NJ (2006) Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 98, 39–49.
177.Damsgaard CT, Frokiaer H, Andersen AD et al. (2008) Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men. J Nutr 138, 1061–1066.
178.Sanders TA, Lewis F, Slaughter S et al. (2006) Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45–70 y: The OPTILIP study. Am J Clin Nutr 84, 513–522.
179.Elvevoll EO, Barstad H, Breimo ES et al. (2006) Enhanced incorporation of n-3 fatty acids from fish compared with fish oils. Lipids 41, 1109–1114.
180.Sanders TA, Gleason K, Griffin B et al. (2006) Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 95, 525–531.
181.Hartweg J, Farmer A, Holman R et al. (2007) Meta-analysis of the effects of n/i-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 50, 250–258.
182.Krämer HJ, Stevens J, Grimminger F et al. (1996) Fish oil fatty acids and human platelets: Dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol 52, 1211–1217.
183.Mayer K, Merfels M, Muhly-Reinholz M et al. (2002) Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: Role of endothelial PAF generation. Am J Physiol Heart Circ Physiol 283, H811–818.
184.Yanagisawa N, Shimada K, Miyazaki T et al. (2010) Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb 17, 285–294.
185.Thorseng T, Witte DR, Vistisen D et al. (2009) The association between n-3 fatty acids in erythrocyte membranes and insulin resistance: The Inuit Health in Transition Study. Int J Circumpolar Health 68, 327–336.
186.Nigam A, Frasure-Smith N, Lesperance F et al. (2009) Relationship between n-3 and n-6 plasma fatty acid levels and insulin resistance in coronary patients with and without metabolic syndrome. Nutr Metab Cardiovasc Dis 19, 264–270.
187.Lombardo Y, Hein G & Chicco A (2007) Metabolic syndrome: Effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity. Lipids 42, 427–437.
188.Arai T, Kim HJ, Chiba H et al. (2009) Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice. J Atheroscler Thromb 16, 674–683.
189.Hartweg J, Perera R, Montori V et al. . (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 23, CD003205.
190.Murata M, Kaji H, Iida K et al. (2001) Dual action of eicosapentaenoic acid in hepatoma cells. J Biol Chem 276, 31422–31428.
191.Li M, Pittman CU Jr & Li T (2009) Extraction of polyunsaturated fatty acid methyl esters by imidazolium-based ionic liquids containing silver tetrafluoroborate – extraction equilibrium studies. Talanta 78, 1364–1370.
192.Andersen G, Harnack K, Erbersdobler HF et al. (2008) Dietary eicosapentaenoic acid and docosahexaenoic acid are more effective than alpha-linolenic acid in improving insulin sensitivity in rats. Ann Nutr Metab 52, 250–256.
193.Shimura T, Miura T, Usami M et al. (1997) Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM). Biol Pharm Bull 20, 507–510.
194.Nomura S, Inami N, Shouzu A et al. (2009) The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 20, 16–22.
195.Egert S, Fobker M, Andersen G et al. (2008) Effects of dietary alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on parameters of glucose metabolism in healthy volunteers. Ann Nutr Metab 53, 182–187.